Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Neulasta Market Forecast: What Value Will The Market Reach By 2030?
The historical expansion can be linked to the increased application of chemotherapy, a growing occurrence of treatment-related neutropenia, the presence of pegylated growth factors, an rise in oncology supportive care guidelines, and the adoption of prefilled injection devices.
The anticipated growth throughout the forecast period is fueled by a heightened need for user-friendly drug administration methods, escalating capital allocated to biosimilar rivalry, the proliferation of cancer care provided in patients’ homes, an intensifying emphasis on patient-focused oncology services, and wider acceptance of sustained-release biological medications.
Significant trends anticipated in the coming period involve a broader uptake of prolonged neutropenia therapies, the growing utilization of wearable drug delivery devices, an enlargement of complementary cancer support services, an increasing inclination towards managing cancer in ambulatory settings, and a sharpened emphasis on patient compliance with prescribed treatments.
Get A Free Sample Report With In-Depth Market Insights:
Neulasta Market Growth Catalysts And Demand Drivers
The increasing occurrence of cancer is a key factor driving the expansion of the neulasta market. Cancer, characterized by abnormal cell growth that can spread throughout the body, is becoming more prevalent, largely due to an aging global population where the risk of developing the disease significantly increases with age. Neulasta, a therapy based on pegfilgrastim, plays a crucial role in cancer care by helping to prevent chemotherapy-induced neutropenia, stimulating the production of white blood cells, and lowering the risk of infections for patients undergoing chemotherapy. For example, data from August 2024 provided by the Australian Institute of Health and Welfare, an Australia-based national agency for health statistics, indicates that Australia is expected to see approximately 209,000 new cancer cases by 2034, an increase from an estimated 169,000 cases in 2024. Furthermore, cancer is projected to cause around three out of every ten deaths in 2024. Consequently, the rising incidence of cancer will propel the neulasta market.
Neulasta Market Segment Breakdown: Which Categories Lead On Revenue?
The neulasta market covered in this report is segmented –
1) By Indication: Chemotherapy-Induced Neutropenia, Bone Marrow Transplantation, Other Indications
2) By Formulation: Injectable Solution, Pre-Filled Syringes Or Pens
3) By Distribution Channel: Hospitals, Oncology Clinics, Specialty Pharmacies, Home Healthcare Services
4) By End User Patients: Adult Patients, Pediatric Patients
Neulasta Market Trends Shaping Long-Term Demand
The primary trend in the neulasta market is the evolution of drug delivery technologies, such as prefilled autoinjectors, to secure a competitive advantage within the industry. Prefilled autoinjectors are self-injection devices that come preloaded with medication, crafted for convenient and effortless patient self-administration. For instance, in March 2023, Coherus Biosciences, a US-based biopharmaceutical company, announced the FDA’s approval of a single-dose, prefilled autoinjector version of its pegfilgrastim biosimilar, Udenyca (pegfilgrastim-cbqv), intended for the treatment and prevention of febrile neutropenia, a common issue arising from chemotherapy. This specific autoinjector enables patients to receive pegfilgrastim the day after chemotherapy, effectively lowering the risk of febrile neutropenia. The device features push-on-skin activation, ensuring reliable and immediate delivery of a full pegfilgrastim dose.
Neulasta Market Leading Players And Competitive Positioning
Major companies operating in the neulasta market are Amgen Inc.
View The Full Neulasta Market Report:
Neulasta Market Geographic Distribution And Regional Opportunities
North America was the largest region in the neulasta market in 2025. The regions covered in the neulasta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
